Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug901 | Canakinumab Injection 300mg Wiki | 0.71 |
| drug902 | Canakinumab Injection 600mg Wiki | 0.71 |
| drug3934 | Serological test Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009220 | Myositis NIH | 0.50 |
| D001528 | Behcet Syndrome NIH | 0.50 |
| D012859 | Sjogren's Syndrome NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100614 | Myositis HPO | 0.50 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.29 |
Navigate: Correlations HPO
There are 2 clinical trials
Sarcoidosis is a heterogeneous disorder of unknown etiology whose signature lesions are granulomatous inflammatory infiltrates in involved tissues. Tissue commonly affected are lungs, skin, eyes, lymph nodes and the heart. In this latter case, cardiac sarcoidosis (CS) can lead to atrioventricular (AV) blocks, ventricular arrhythmias, heart failure (HF) and sudden cardiac death. Similar to other involved organs, cardiac disease generally progresses from areas of focal inflammation to scar. However, the natural history of CS is not well characterized complicating an immediate and definitive diagnosis. The management of CS often requires multidisciplinary care teams and is challenged by data limited to small observational studies and from the high likelihood of side effects of most of the treatments currently used (eg: corticosteroids, methotrexate and TNF-alfa inhibitors). Interleukin-1 (IL-1) is the prototypical pro-inflammatory cytokine, also referred to as master regulator of the inflammatory response, involved in virtually every acute process. There is evidence that IL-1 plays a role in mouse model of sarcoidosis and human pulmonary lesions as the presence of the inflammasome in granulomas of the heart of patients with cardiac sarcoidosis, providing additional support for a role of IL-1 in the pathogenesis of CS. However, IL-1 blockade has never been evaluated as a potential therapeutic agent for cardiac sarcoidosis. In the current study, researchers aim to evaluate the safety and efficacy of IL-1 blockade with anakinra (IL-1 receptor antagonist) in patients with cardiac sarcoidosis.
Description: Change in c-reactive protein in participant plasma samples
Measure: Change in inflammation marker Time: Baseline to 28 daysDescription: Change in heart function as measured by tracer activity using positron emission tomography (PET) scans
Measure: Change in cardiac inflammation Time: Baseline to 28Description: Change in late gadolinium enhancement evident on magnetic resonance imaging (MRI) scan
Measure: Change in cardiac fibrosis Time: Baseline to 28Description: Sum of hospitalizations and deaths due to cardiac causes
Measure: Number of serious cardiac events Time: 28 daysAn observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease, Rheumatoid arthritis and Spondyloarthritis
Description: Number of patients with positive serological test of SARS Cov2
Measure: Serological Profile Time: InclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports